Free Trial
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel Free EYPT Stock Alerts

Eyepoint Pharmaceuticals (EYPT) Competitors

Eyepoint Pharmaceuticals logo
$13.75 -0.10 (-0.72%)
Closing price 04:00 PM Eastern
Extended Trading
$13.93 +0.18 (+1.28%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

EYPT vs. AEHR, TXG, ALMR, ALNT, and TRNS

Should you be buying Eyepoint Pharmaceuticals stock or one of its competitors? The main competitors of Eyepoint Pharmaceuticals include Aehr Test Systems (AEHR), 10x Genomics (TXG), Alamar Biosciences (ALMR), Allient (ALNT), and Transcat (TRNS). These companies are all part of the "measuring and control equipment" industry.

How does Eyepoint Pharmaceuticals compare to Aehr Test Systems?

Eyepoint Pharmaceuticals (NASDAQ:EYPT) and Aehr Test Systems (NASDAQ:AEHR) are both measuring and control equipment companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, media sentiment, dividends, risk, profitability and institutional ownership.

99.4% of Eyepoint Pharmaceuticals shares are owned by institutional investors. Comparatively, 69.7% of Aehr Test Systems shares are owned by institutional investors. 4.5% of Eyepoint Pharmaceuticals shares are owned by company insiders. Comparatively, 6.8% of Aehr Test Systems shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Eyepoint Pharmaceuticals has a beta of 1.76, meaning that its share price is 76% more volatile than the S&P 500. Comparatively, Aehr Test Systems has a beta of 3.26, meaning that its share price is 226% more volatile than the S&P 500.

Aehr Test Systems has a net margin of -25.23% compared to Eyepoint Pharmaceuticals' net margin of -739.39%. Aehr Test Systems' return on equity of -7.15% beat Eyepoint Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Eyepoint Pharmaceuticals-739.39% -88.31% -72.52%
Aehr Test Systems -25.23%-7.15%-6.15%

In the previous week, Aehr Test Systems had 5 more articles in the media than Eyepoint Pharmaceuticals. MarketBeat recorded 9 mentions for Aehr Test Systems and 4 mentions for Eyepoint Pharmaceuticals. Aehr Test Systems' average media sentiment score of 0.69 beat Eyepoint Pharmaceuticals' score of 0.26 indicating that Aehr Test Systems is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Eyepoint Pharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Aehr Test Systems
3 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Eyepoint Pharmaceuticals presently has a consensus price target of $32.20, indicating a potential upside of 134.18%. Aehr Test Systems has a consensus price target of $68.00, indicating a potential downside of 25.43%. Given Eyepoint Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Eyepoint Pharmaceuticals is more favorable than Aehr Test Systems.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Eyepoint Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
2 Strong Buy rating(s)
3.00
Aehr Test Systems
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40

Aehr Test Systems has higher revenue and earnings than Eyepoint Pharmaceuticals. Aehr Test Systems is trading at a lower price-to-earnings ratio than Eyepoint Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eyepoint Pharmaceuticals$31.37M36.73-$231.96M-$3.16N/A
Aehr Test Systems$58.97M48.63-$3.91M-$0.38N/A

Summary

Aehr Test Systems beats Eyepoint Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does Eyepoint Pharmaceuticals compare to 10x Genomics?

Eyepoint Pharmaceuticals (NASDAQ:EYPT) and 10x Genomics (NASDAQ:TXG) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, media sentiment, dividends, risk, profitability and institutional ownership.

99.4% of Eyepoint Pharmaceuticals shares are owned by institutional investors. Comparatively, 84.7% of 10x Genomics shares are owned by institutional investors. 4.5% of Eyepoint Pharmaceuticals shares are owned by company insiders. Comparatively, 8.8% of 10x Genomics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Eyepoint Pharmaceuticals has a beta of 1.76, meaning that its share price is 76% more volatile than the S&P 500. Comparatively, 10x Genomics has a beta of 2.05, meaning that its share price is 105% more volatile than the S&P 500.

10x Genomics has a net margin of -6.77% compared to Eyepoint Pharmaceuticals' net margin of -739.39%. 10x Genomics' return on equity of -6.89% beat Eyepoint Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Eyepoint Pharmaceuticals-739.39% -88.31% -72.52%
10x Genomics -6.77%-6.89%-5.34%

In the previous week, 10x Genomics had 1 more articles in the media than Eyepoint Pharmaceuticals. MarketBeat recorded 5 mentions for 10x Genomics and 4 mentions for Eyepoint Pharmaceuticals. 10x Genomics' average media sentiment score of 0.47 beat Eyepoint Pharmaceuticals' score of 0.26 indicating that 10x Genomics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Eyepoint Pharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
10x Genomics
1 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Eyepoint Pharmaceuticals presently has a consensus price target of $32.20, indicating a potential upside of 134.18%. 10x Genomics has a consensus price target of $20.82, indicating a potential downside of 5.40%. Given Eyepoint Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Eyepoint Pharmaceuticals is more favorable than 10x Genomics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Eyepoint Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
2 Strong Buy rating(s)
3.00
10x Genomics
2 Sell rating(s)
9 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.29

10x Genomics has higher revenue and earnings than Eyepoint Pharmaceuticals. 10x Genomics is trading at a lower price-to-earnings ratio than Eyepoint Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eyepoint Pharmaceuticals$31.37M36.73-$231.96M-$3.16N/A
10x Genomics$642.82M4.37-$43.54M-$0.35N/A

Summary

10x Genomics beats Eyepoint Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Eyepoint Pharmaceuticals compare to Alamar Biosciences?

Alamar Biosciences (NASDAQ:ALMR) and Eyepoint Pharmaceuticals (NASDAQ:EYPT) are both small-cap measuring and control equipment companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations, profitability and earnings.

Eyepoint Pharmaceuticals has a consensus target price of $32.20, suggesting a potential upside of 134.18%. Given Eyepoint Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Eyepoint Pharmaceuticals is more favorable than Alamar Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alamar Biosciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Eyepoint Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
2 Strong Buy rating(s)
3.00

In the previous week, Eyepoint Pharmaceuticals had 2 more articles in the media than Alamar Biosciences. MarketBeat recorded 4 mentions for Eyepoint Pharmaceuticals and 2 mentions for Alamar Biosciences. Eyepoint Pharmaceuticals' average media sentiment score of 0.26 beat Alamar Biosciences' score of 0.00 indicating that Eyepoint Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Alamar Biosciences
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Eyepoint Pharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Alamar Biosciences has higher revenue and earnings than Eyepoint Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alamar Biosciences$74.21M21.42N/AN/AN/A
Eyepoint Pharmaceuticals$31.37M36.73-$231.96M-$3.16N/A

Alamar Biosciences has a net margin of 0.00% compared to Eyepoint Pharmaceuticals' net margin of -739.39%. Alamar Biosciences' return on equity of 0.00% beat Eyepoint Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Alamar BiosciencesN/A N/A N/A
Eyepoint Pharmaceuticals -739.39%-88.31%-72.52%

99.4% of Eyepoint Pharmaceuticals shares are held by institutional investors. 4.5% of Eyepoint Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Eyepoint Pharmaceuticals beats Alamar Biosciences on 9 of the 13 factors compared between the two stocks.

How does Eyepoint Pharmaceuticals compare to Allient?

Allient (NASDAQ:ALNT) and Eyepoint Pharmaceuticals (NASDAQ:EYPT) are both small-cap measuring and control equipment companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations, profitability and earnings.

Allient currently has a consensus target price of $70.75, suggesting a potential downside of 9.29%. Eyepoint Pharmaceuticals has a consensus target price of $32.20, suggesting a potential upside of 134.18%. Given Eyepoint Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Eyepoint Pharmaceuticals is more favorable than Allient.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Allient
0 Sell rating(s)
3 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
Eyepoint Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
2 Strong Buy rating(s)
3.00

In the previous week, Allient had 4 more articles in the media than Eyepoint Pharmaceuticals. MarketBeat recorded 8 mentions for Allient and 4 mentions for Eyepoint Pharmaceuticals. Allient's average media sentiment score of 0.64 beat Eyepoint Pharmaceuticals' score of 0.26 indicating that Allient is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Allient
4 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Eyepoint Pharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Allient has a beta of 1.65, meaning that its stock price is 65% more volatile than the S&P 500. Comparatively, Eyepoint Pharmaceuticals has a beta of 1.76, meaning that its stock price is 76% more volatile than the S&P 500.

Allient has higher revenue and earnings than Eyepoint Pharmaceuticals. Eyepoint Pharmaceuticals is trading at a lower price-to-earnings ratio than Allient, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Allient$554.48M2.39$22.03M$1.3259.09
Eyepoint Pharmaceuticals$31.37M36.73-$231.96M-$3.16N/A

Allient has a net margin of 3.97% compared to Eyepoint Pharmaceuticals' net margin of -739.39%. Allient's return on equity of 12.53% beat Eyepoint Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Allient3.97% 12.53% 6.21%
Eyepoint Pharmaceuticals -739.39%-88.31%-72.52%

61.6% of Allient shares are held by institutional investors. Comparatively, 99.4% of Eyepoint Pharmaceuticals shares are held by institutional investors. 15.0% of Allient shares are held by company insiders. Comparatively, 4.5% of Eyepoint Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Allient beats Eyepoint Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Eyepoint Pharmaceuticals compare to Transcat?

Transcat (NASDAQ:TRNS) and Eyepoint Pharmaceuticals (NASDAQ:EYPT) are both small-cap measuring and control equipment companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, analyst recommendations, dividends, profitability, valuation, risk and earnings.

98.3% of Transcat shares are held by institutional investors. Comparatively, 99.4% of Eyepoint Pharmaceuticals shares are held by institutional investors. 2.8% of Transcat shares are held by company insiders. Comparatively, 4.5% of Eyepoint Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Transcat has a beta of 0.68, meaning that its share price is 32% less volatile than the S&P 500. Comparatively, Eyepoint Pharmaceuticals has a beta of 1.76, meaning that its share price is 76% more volatile than the S&P 500.

In the previous week, Eyepoint Pharmaceuticals had 2 more articles in the media than Transcat. MarketBeat recorded 4 mentions for Eyepoint Pharmaceuticals and 2 mentions for Transcat. Transcat's average media sentiment score of 1.30 beat Eyepoint Pharmaceuticals' score of 0.26 indicating that Transcat is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Transcat
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Eyepoint Pharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Transcat currently has a consensus price target of $105.33, suggesting a potential upside of 39.83%. Eyepoint Pharmaceuticals has a consensus price target of $32.20, suggesting a potential upside of 134.18%. Given Eyepoint Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Eyepoint Pharmaceuticals is more favorable than Transcat.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Transcat
2 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.40
Eyepoint Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
2 Strong Buy rating(s)
3.00

Transcat has higher revenue and earnings than Eyepoint Pharmaceuticals. Eyepoint Pharmaceuticals is trading at a lower price-to-earnings ratio than Transcat, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Transcat$278.42M2.52$14.52M$0.8588.62
Eyepoint Pharmaceuticals$31.37M36.73-$231.96M-$3.16N/A

Transcat has a net margin of 2.47% compared to Eyepoint Pharmaceuticals' net margin of -739.39%. Transcat's return on equity of 6.15% beat Eyepoint Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Transcat2.47% 6.15% 4.15%
Eyepoint Pharmaceuticals -739.39%-88.31%-72.52%

Summary

Eyepoint Pharmaceuticals beats Transcat on 9 of the 17 factors compared between the two stocks.

Get Eyepoint Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for EYPT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EYPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EYPT vs. The Competition

Export
MetricEyepoint PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$1.16B$3.40B$6.25B$11.77B
Dividend YieldN/A2.23%2.74%5.26%
P/E Ratio-4.3538.5729.2527.07
Price / Sales36.73280.02504.6873.47
Price / CashN/A125.0643.3053.90
Price / Book3.727.059.676.69
Net Income-$231.96M$23.62M$3.55B$332.64M
7 Day Performance2.08%3.67%1.70%2.01%
1 Month Performance2.61%7.17%5.62%9.19%
1 Year Performance100.44%67.04%34.42%39.59%

Eyepoint Pharmaceuticals Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
EYPT
Eyepoint Pharmaceuticals
2.6465 of 5 stars		$13.75
-0.7%		$32.20
+134.2%		N/A$1.16B$31.37MN/A120
AEHR
Aehr Test Systems
1.5335 of 5 stars		$91.88
+7.3%		$68.00
-26.0%		N/A$2.88B$45.26MN/A90
TXG
10x Genomics
1.1762 of 5 stars		$21.83
+0.8%		$20.82
-4.6%		N/A$2.79B$642.82MN/A1,240
ALMR
Alamar Biosciences
N/A$23.92
+0.7%		N/AN/A$1.59B$74.21MN/A222
ALNT
Allient
2.8913 of 5 stars		$79.27
+4.8%		$70.75
-10.7%		N/A$1.35B$554.48M60.022,478

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:EYPT) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel